Mineralocorticoid receptor p.l180V polymorphism: Association with body mass index and LDL-cholesterol levels

作者：Fernandes Rosa F L; Bueno A C; de Souza R Molina; de Castro M; dos Santos J Ernesto; Foss M C; Zennaro M C; Bettiol H; Barbieri M A; Antonini S R^*

来源：Journal of Endocrinological Investigation, 2010, 33(7): 472-477.

DOI：10.3275/6718

• Cardiometabolic risk
• hypertension
• mineralocorticoid receptor
• obesity
• polymorphism

Background/Aims: Aldosterone and the mineralocorticoid receptor (MR) play a major role in sodium balance and blood pressure control. They are also involved in adipocyte metabolism. The aim of this study was to analyze the association between the MR p.l180V polymorphism with hypertension and markers of cardiovascular risk. Design and methods: Case-control study nested within a cohort of 2063 subjects followed since birth to date. All subjects (age 23-25 yr old) from the entire cohort with systolic and diastolic hypertension (no.=126) were paired with 398 normotensive controls. MR p.l180V genotype association with anthropometric and biochemical markers of cardiometabolic risk was tested. Results: There was a significant association of the MR p.l180V genotype with body mass index (BMI) and LDL-cholesterol level (p<0.01). Hypertensive subjects carrying the polymorphic G allele (AG or GG genotypes) presented significantly higher BMI (30.0 +/- 6.0 vs 28.7 +/- 5.6 kg/m(2); p<0.01) and higher LDL-cholesterol (139.9 +/- 60.3 vs 109.9 +/- 35.5 mg/dl; p<0.01). The frequency of the polymorphism MR p.l180V was similar between hypertensive subjects and controls (p=0.15). Conclusions: The MR p.l180V polymorphism seems to be associated with cardiovascular risk factors including BMI and LDL-cholesterol levels. This original in vivo finding reinforces the role of MR in adipocyte biology and in cardiovascular disease. (J. Endocrinol. Invest.

• 出版日期2010-8